Doctor discussing medication with teenage

Optimmize (M19-973)

A Phase III trial looking at the long-term safety and effectiveness of risankizumab in children and young people aged 6 to 17 with moderate to severe plaque psoriasis.

Doctor discussing medication with teenage

About Optimmize

Plaque psoriasis is a chronic inflammatory skin condition that causes raised, red, scaly patches on the skin and can have a significant impact on the physical and emotional wellbeing of children and young people. Although effective treatments are available, further research is needed to understand the long-term safety and benefits of these therapies in paediatric populations. The OPTIMMIZE study is a Phase III clinical trial evaluating the long-term safety, tolerability, and effectiveness of risankizumab in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. Through regular clinical assessments and extended follow-up, the study aims to monitor how well treatment maintains disease control while assessing its safety over time. The results will contribute to the growing evidence base for biologic therapies in paediatric psoriasis and help improve long-term treatment strategies for children and young people living with this chronic skin condition.

Study details

Condition

Psoriasis

Drug

Risankizumab

Age range

6-17

Funder

AbbVie